Biotechnology in Thoughts from the Centre

Who will win the race to develop an effective treatment for COVID-19

By Karen Taylor, Director, Centre for Health Solutions

Covid

Our previous reports have highlighted the increasing number of innovations that have led to life-saving and life-enhancing clinical treatments and how, over the past 30 or so years, healthcare has moved from treating infectious or communicable diseases to managing a ‘tidal wave’ of complex age and behaviour related, non-communicable, diseases.1 This transition was made possible by the development and widespread use of vaccines and antibiotics which dramatically reduced the prevalence and improved outcomes for most infectious diseases. Today, this scenario has been turned on its head as people across the world face the unrelenting human and economic impact from a novel, infectious, coronavirus SARS-CoV-2 (named COVID-19 disease). On 11th March the World Health Organisation (WHO) declared COVID-19 a pandemic, and the biopharma industry is now in a race to develop both preventive and therapeutic interventions.

Continue reading

Posted on 27/03/2020 | 0 Comments

The Indian pharmaceutical industry: The ‘pharmacy of the world’?

By Pratik Avhad, Senior Analyst, Insight

Indian-pharma

The Indian pharmaceutical (pharma) industry has an annual revenue of US$38 billion – globally it’s the third largest in the world by volume and 11th by value. It comprises over 3,000 pharma companies and 10,500 manufacturing facilities. It also produces drugs at around a third of the US costs and half of the European costs. Moreover, Indian pharma companies supply around 20 per cent of the worlds’ generics and 50 per cent of its vaccines.1,2 This is the first of three blogs exploring the past, present and future of the Indian pharma market. This first blog examines the evolution of the industry, with subsequent ones exploring the transformations now underway, and the likely future for the industry.

Continue reading

Posted on 20/03/2020 | 0 Comments

How AI could improve the odds of finding treatments for rare diseases

By Maria João Cruz, Research Analyst, and Dr Francesca Properzi, PhD, Research Manager, Centre for Health Solutions

AI

February 29, a pretty rare date, was this year’s Rare Disease Day, a campaign to raise awareness among the public and policy makers on rare diseases and how they impact the lives of patients and their loved ones.1 Indeed, the advocacy, commitment and tenacity of rare disease patient organisations have played a critical role in elevating ‘rare diseases’ as an emerging global public health priority. Particularly in advocating for legislation to develop drugs and treatment programmes that will meet patients’ needs. In today’s blog we highlight the importance of rare diseases and, in particular, the opportunities that artificial intelligence (AI) tools offer to speed-up the discovery of new treatments.

Continue reading

Posted on 06/03/2020 | 0 Comments

What are the key considerations for biotech European expansion?

By Juan Salcines Gomez-Pardo, Consultant, Monitor Deloitte

Biotech

Small to medium sized life sciences companies are now at the forefront of innovation in the search for new cures and hope for patients. However, many biotech and medtech companies face significant challenges in navigating the business life cycle. Monitor Deloitte colleagues Li Xiaofeng, Hanno Ronte and James Forsyth have recently published our latest thinking on ‘Biotech-in-a-boxTM: ‘How to ‘ACE’ geographical expansion in Europe’. This report introduces a three-step game plan to support biotech and medtech companies to thrive in an increasingly challenging environment, de-risk attempts to scale up adoption of technologies and improve success in geographical expansion. This week’s blog by our colleague, Juan Salcines, highlights the key findings from this report, based on his recent experience working with biotech companies across Europe.

Continue reading

Posted on 21/02/2020 | 0 Comments

Intelligent clinical trials: Transforming through AI-enabled engagement

By Dr Francesca Properzi, PhD. Research Manager, and Maria João Cruz, Research Analyst, Centre for Health Solutions

Clinical-trial

This week we launched the third report in our series on the impact of artificial intelligence (AI) across the biopharma value chain. This latest report, Intelligent clinical trials: Transforming through AI-enabled engagement, explores how AI, in particular machine learning and natural language processing, can reduce clinical trial cycle times while reducing the costs and improving the productivity and outcomes of clinical development. In this blog, we highlight the main takeaways from our report.

Continue reading

Posted on 13/02/2020 | 0 Comments

M&A in R&D: How innovative and unfamiliar acquisitions can unlock R&D productivity

By David Tullett, Consultant, Deloitte MCS Limited

Ma-blog-image

Earlier this month our colleagues published their report, The role of innovative and unfamiliar acquisitions in unlocking R&D productivity, which looks at the impact of M&A on the pharma landscape and outlines how external innovation is impacting pharmaceutical R&D and the reasons behind the projected growth in deal volume for 2020. This week’s blog by our colleague, David Tullett, who worked closely on the above report with Heena Dodhia and Mark Stockbridge, provides his view on the key takeaways.

Continue reading

Posted on 24/01/2020 | 0 Comments

2020 global life sciences outlook: Creating new value, building blocks for the future

By Dr Mark Steedman, PhD, Manager, Centre for Health Solutions

Ls-outlook

Each January, Deloitte produces a report exploring the outlook for the life sciences sector. This year’s report, 2020 global life sciences outlook: Creating new value, building blocks for the future, explores how biopharma and medtech organisations can harness a future driven by evolving data-driven technologies and remain relevant in an ever-evolving business landscape. Organisations should look for ways to create new value, adopt new metrics to take advantage of the wealth of data available today and rethink what is being measured.

Continue reading

Posted on 17/01/2020 | 0 Comments

Ten years on: Measuring the return from pharmaceutical innovation 2019

By Maria João Cruz, Research Analyst, Centre for Health Solutions

Pharma

This week, we published the tenth in our series of annual reports, Measuring the return from pharmaceutical innovation. For the past decade we have used a consistent and objective methodology to provide analyses and insights on the R&D productivity of the top 12 biopharma companies (original cohort), and the returns they can expect to achieve from their late stage pipelines. For five years, we have contrasted our original cohort’s performance with the performance of four smaller, more specialised companies, which we tracked back to 2013. While our findings have demonstrated a systemic, cross-company, decade-long decline in the productivity of R&D, we have also witnessed significant advances in science and the development of innovative therapies delivering impressive improvements in health outcomes.

Continue reading

Posted on 19/12/2019 | 0 Comments

The FT Global Pharmaceutical and Biotechnology Conference 2019: Forces disrupting the industry

By Karen Taylor, Director, Centre for Health Solutions

Ftg

Last month Deloitte was one of the main sponsors of the 2019 FT Global Pharmaceutical and Biotechnology Conference. This is a key event for the industry, attended by senior industry executives and financial professionals from around the world. The aim of this year’s conference was to focus a critical eye on the forces set to transform the industry in the years ahead. I was privileged to attend the conference and help man our stall where we displayed our research reports, including our report Intelligent biopharma: Powered by AI, which we launched on the first day. We also introduced our new Converge Health platform and the connected patient experience. This week’s blog shares some of the highlights that I took away from the presentations and panel debates that took place on the first day. I will return to day two in a later blog.

Continue reading

Posted on 06/12/2019 | 0 Comments

Intelligent drug discovery: Powered by AI

By Dr Francesca Properzi, PhD. Research Manager, Centre for Health Solutions

Deloitte-uk-intelligent-drug-discovery

Next week at the 2019 Global Financial Times Pharmaceutical and Biotechnology conference in London, we will formally launch the second in our series of reports on how artificial intelligence (AI) is driving the digital transformation of biopharma. This second report, Intelligent drug discovery: Powered by AI, explores the rise of ‘disruptive AI for drug discovery’ companies and the challenges and opportunities for biopharma in using AI technologies to help find new, more precise, targeted treatments.1 This blog highlights the key takeaways from our report.

Continue reading

Posted on 08/11/2019 | 0 Comments